Azelon Pharmaceuticals (West Conshohocken, PA) a preclinical-stage pharmaceutical company focused on osteoporosis, closed a $4.5M Series A financing. Participants include Prospect Venture Partners, Lighthouse Capital Partners and Covington Venture Fund.

Dfine (San Jose, CA) a commercial-stage medical device company focused on minimally invasive therapeutic devices used to treat pathologies of the vertebrae, closed a $25 million Series E financing. Participants include OrbiMed, Prospect Venture Partners, Split Rock Partners, BBT Capital, Highland Capital Management and Vanguard Ventures.

Topica Pharmaceuticals (Palo Alto, CA) a clinical-stage pharmaceutical company focused on treatments for onychomycosis, closed a $27M Series B financing. Participants include Third Rock Ventures, Prospect Venture Partners and Yasuda Enterprise Development Corporation.

Kythera Biopharmaceuticals (Calabasas, CA) a clinical-stage biopharmaceutical company focused on aesthetic dermatology, closed a $37.4M Series D financing. Participants include Versant Ventures, Arch Venture Partners, Prospect Venture Partners, Jafco Ventures, Invus Financial Advisors, BBT Capital Management, Altitude Life Science Ventures and Foley Ventures.

Nine Point Medical (Cambridge, MA) a development-stage medical device and diagnostic company focused on optical technologies for real-time in vivo pathology decision making, closed a $33M Series A financing. Participants include Third Rock Ventures and Prospect Venture Partners. _________________________________________________________________________ OnBioVC is exceedingly thankful for among many things the steadfast support for all of our readers [...]

Pathwork Diagnostics (Redwood City, CA) a commercial-stage molecular diagnostics company focused on tumor RNA expression patterns, closed a $30M Series C financing, it announced. Participants include Alta Partners, Abingworth, Advent Venture Partners, Novus Ventures, Prospect Venture Partners and Venrock.

Complete Genomics (Mountain View, CA) a commercial-stage sequencing company building a human genome sequencing center to enable academic and biopharma researchers to conduct large-scale human genome studies, closed a $39M Series E financing. Participants include Sands Capital Management, Essex Woodlands, OVP Venture Partners, Prospect Venture Partners, OrbiMed Advisors, Highland Capital Management and Enterprise Partners.

Boxano (Mountain View, CA) a commercial-stage medical device company focused on lumbar spinal stenosis, closed a $30M Series C financing. Participants include CMEA Capital, Kaiser Permanente Ventures, Affinity Capital Management, Prospect Venture Partners, Three Arch Partners and Kearny Venture Partners.

NGM Biopharmaceuticals (San Francisco, CA) a preclinical-stage biopharmaceutical company focused on diabetes, obesity and muscle wasting, closed a $51M Series B financing. Participants include The Column Group, Tichenor Ventures, Prospect Venture Partners and Rho Ventures.

Neomend (Irvine, CA) a commercial-stage developer of sealant and adhesion-prevemtion products focused on the application to visceral pleura for open thoracotomy, closed a $30M Series D financing. Participants include Clarus Ventures, Sanderling Ventures, Novo Ventures, Vivo Ventures and Prospect Venture Partners.

Lux Biosciences (Jersey City, NJ) a clinical-stage biotechnology company focused on ophthalmic diseases, closed a $50M Series B financing. Participants include HBM Bioventures, De Novo Ventures, Prospect Venture Partners, SV Life Sciences and International Biotechnology Trust. Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.